A Study of the Effects of Ranolazine Using Automated Quantitative Analysis of Serial Myocardial Perfusion Images  by Venkataraman, Rajesh et al.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 2 , N O . 1 1 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 0 9 . 0 9 . 0 0 6A Study of the Effects of Ranolazine
Using Automated Quantitative Analysis of
Serial Myocardial Perfusion Images
Rajesh Venkataraman, MD, MPH,* Luiz Belardinelli, MD,† Brent Blackburn, PHD,†
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O B J E C T I V E S This study examined the hypothesis that the improvement in myocardial blood ﬂow
(MBF) with ranolazine therapy could be detected by serial automated quantitative myocardial perfusion
imaging (MPI) in patients with coronary artery disease (CAD) and myocardial ischemia.
B A C KG ROUND Myocardial ischemia enhances late sodium current, which then causes cellular
calcium overload leading to mechanical left ventricular dysfunction and arrhythmias. Ranolazine inhibits
late sodium current and improves diastolic tension and MBF in the animal model.
METHOD S In this open-label, nonrandomized pilot study, we recruited 20 patients with known or
a high probability of CAD and who had reversible perfusion defects on exercise treadmill gated
single-photon emission computed tomography MPI while receiving conventional antianginal therapy.
Ranolazine (up to 1,000 mg twice daily) was added to baseline therapy and a repeat treadmill MPI was
obtained after 4 weeks. The extent and severity of total and reversible left ventricular perfusion
abnormality (based on polar maps and a 17-segment model) were determined quantitatively using
automated methods.
R E S U L T S We screened 100 patients for 27 potential candidates; 5 declined and 2 did not complete
the follow-up study. The mean age of the remaining 20 patients was 64  9 years; 30% were women
and 50% had diabetes mellitus. The exercise time increased (425  105 s vs. 393  116 s, p  0.017),
and angina improved in 15 (75%) patients after ranolazine treatment. In the entire cohort, summed
stress scores (10 7 vs. 13 8, p 0.04) and summed difference scores (4.7 4 vs. 7.4 5, p 0.0037)
decreased at follow-up. An improvement in perfusion pattern and severity was noted in 14 (70%)
patients. In these patients, the polar maps showed a decrease in total abnormality from 26  17% to 19
 15% and a decrease in the reversible abnormality from 16  10% to 8  6% (all p values 0.05).
CONC L U S I O N S In this preliminary hypothesis-driven study, short-term ranolazine therapy was
shown to improve myocardial perfusion and decrease the ischemic burden in patients with CAD. (J Am
Coll Cardiol Img 2009;2:1301–9) © 2009 by the American College of Cardiology Foundation
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1302oronary artery disease (CAD) is a leading
cause of death and disability in the U.S.,
and despite many advances, chronic stable
angina is present in 9.0 million Ameri-
ans (3% of the entire population) (1). Many of
he conventional medications such as beta-
drenergic blocking agents, calcium channel block-
rs, nitrates, and lipid-lowering drugs have been
hown to improve symptoms and ameliorate myo-
ardial ischemia (2). Ranolazine, a prototype of a
ate sodium current inhibitor, has recently been
pproved as first-line treatment in patients with
See page 1310
ngina based on studies showing that it increases
ime to angina and total treadmill exercise time and
educes the frequency of angina (3–10).
In an animal model, ranolazine increases myo-
ardial blood flow (MBF), possibly because inhibi-
tion of late sodium current results in a
decrease in left ventricular (LV) stiffness,
which in turn decreases extravascular com-
pressive forces on coronary microcircula-
tion and thereby improves MBF (11–14).
Such an improvement in MBF is likely to
contribute to the antianginal effects of
ranolazine. However, there are no data on
the effect of ranolazine on myocardial
perfusion or MBF in patients with CAD.
Thus, the objective of this pilot study was
to determine whether ranolazine improves
myocardial perfusion during exercise in
atients with CAD as assessed by serial automated
uantitative myocardial perfusion imaging (MPI).
E T H O D S
his was an open-label study conducted at the Uni-
ersity of Alabama at Birmingham Medical Center
nd approved by its institutional review board, and all
articipants signed an informed consent form. The
tudy design and data collection, interpretation, and
eporting were the responsibility of the University of
labama at Birmingham faculty.
Patients older than the age of 18 years with
ngina or angina equivalent (chest pain or shortness
f breath) on optimal tolerated medical therapy
ho met the inclusion/exclusion criteria (Table 1)
nd had reversible perfusion defects on baseline
PI (either clinically indicated or as a part of the
tudy protocol) were entered into the study. It
se
w
core
ssionhould be noted that these patients did not have Cisabling angina, and the study was not designed to
tudy the effects of ranolazine treatment on angina
requency but rather on myocardial perfusion.
Patients were given ranolazine as an add-on to
heir baseline medications in doses of 500 mg twice
aily for 1 week and then 1,000 mg twice daily for
weeks. The doses of other medications were not
ltered during the 4 weeks of ranolazine therapy.
fter 4 weeks, a second exercise treadmill MPI was
erformed. The duration of therapy in previous
lacebo-controlled studies with ranolazine ranged
rom 1 to 12 weeks (5,9). We chose to use 4 weeks
f therapy to ensure adequate compliance and
p-titration to 2 g/day dosing and any unexpected
hanges in clinical status of the patient. Patients
ere closely followed by weekly telephone calls to
ssess for any adverse effects and compliance.
Demographic, clinical, and pertinent laboratory
ata were recorded at enrollment. Angina or angina
quivalent severity, according to the Canadian Car-
iovascular Society anginal class, was assessed at
aseline and after treatment with ranolazine. At the
ime of the second exercise MPI, the patients were
lso asked, “how do you feel since your first imaging
tudy: the same, better, or worse?”
readmill exercise testing. The treadmill exercise
as performed using a standard Bruce protocol
15). Patients were allowed to exercise until an
xercise end-point was reached (moderate to severe
ngina, shortness of breath, fatigue or leg weakness,
2 mm ST-segment depression, hypotension, or
evere arrhythmias). Technetium-99m sestamibi
as injected at near-peak exercise, and the patients
ere asked to continue exercise for an additional
inute. Electrocardiographic tracings were re-
orded at 30-s intervals and continued into recov-
ry, until the heart rate returned to baseline. Heart
ate, blood pressure, and QT measurements were
erformed at rest and peak exercise.
The second treadmill exercise test was done in a
imilar fashion, and the same radiotracer was in-
ected at the same exercise time as the initial test,
lthough the patient was allowed to exercise longer
o achieve 1 of the previously cited end points if he
r she could do so. This feature of the study design
llowed comparison of the perfusion images at
imilar exercise levels, but it also allowed determi-
ation of improvement in exercise capacity if such
xisted.
ingle-photon emission computed tomography
SPECT). All images were acquired and processed
ccording to the American Society of NuclearB B R E V I A T I O N S
N D A C R O N YM S
AD coronary artery disea
V left ventricular
BFmyocardial blood flo
PImyocardial perfusion
maging
DS summed difference s
PECT single-photon emiardiology guidelines using either single-day or
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1303-day (depending on body weight) stress/rest–
echnetium-99m sestamibi (15). Imaging was
tarted 60 min after the tracer injection at rest or
xercise. Identical doses of the tracer were used for
he baseline and follow-up studies. All raw data of
ated SPECT images (2 sets per patient) were
econstructed using standard back-projection and
dentical filtering (Butterworth filter with a critical
requency of 0.4 cycles/s, order 5). Motion correc-
ion was applied before image reconstruction if 1
ixel of x or y axis deviation was observed over the
80° acquisition. No attenuation correction was
sed.
Quantitative SPECT was performed using a
reviously validated automated program that deter-
ines the extent and severity of LV perfusion
efect size and the extent of reversible (ischemia) or
xed (scar) perfusion defects (16). LV defect sever-
ty within abnormally perfused regions was defined
n a pixel-by-pixel basis as mild, moderate, or
evere based on its relationship to expected normal
ixel count activity (50%, 26% to 50%, and 0% to
5%, respectively). Severity of ischemia was calcu-
ated as the percentage of count improvement
oward normal values within ischemic pixels and
Table 1. Inclusion and Exclusion Criteria
Inclusion Criteria (>1 of the Following)
1. Abnormal coronary angiogram showing 50% stenosis in
1 epicardial vessels
2. Previous coronary artery revascularization
3. Previous myocardial infarction
4. Abnormal exercise myocardial perfusion imaging and a high
pre-test likelihood of coronary artery disease
Exclusion Criteria
1. Left bundle branch block
2. Pacemaker rhythm
3. Coronary artery bypass graft surgery within past 2 months
4. Acute myocardial infarction within past 2 weeks
5. Percutaneous coronary intervention within past 1 month
6. Ongoing diltiazem therapy
7. Unstable angina
8. Atrial ﬁbrillation
9. Life-threatening arrhythmias
10. Severe heart failure
11. Left ventricular ejection fraction 30%
12. Clinically signiﬁcant valvular or congenital heart disease
13. Severe pulmonary hypertension
14. Women of childbearing age at potential risk of pregnancy
15. Patients already receiving ranolazine therapy
16. Unwilling to provide consentefined as minimal (0% to 25% improvement), boderate (2% to 50% improvement), or marked
50% improvement).
In addition, the automated program was used to
erive the summed stress score, summed rest score,
nd summed difference score (SDS) based on con-
entional 17-segment model. The program as-
igned a score of 0 to 4 to each segment based on
ctivity level: 0  normal and 4  absent. All data
eported here are based on automated analysis of
he data. In addition to perfusion data, the LV
jection fraction, end-diastolic volume, and end-
ystolic volume were measured from the gated
PECT as previously described (16).
At the conclusion of the protocol, the images
ere again interpreted side by side in a blinded
ashion by 1 reader to qualitatively grade the per-
usion pattern as improved, worsened, or no
hange.
tatistical analysis. Data are expressed as percent-
ges for discrete variables and mean  SD for
ontinuous variables. Descriptive statistics were
omputed for MPI and treadmill exercise variables
nd were compared between baseline and follow-up
ests using paired t tests. All statistical analyses were
erformed by 1 of the authors (R.V.) using SAS
ersion 9.1 (SAS Inc., Cary, North Carolina). All
ests were 2-tailed, and a p value 0.05 was used as
he level of significance.
E S U L T S
e screened 100 patients for 27 potential candi-
ates; 5 declined because of long travel time, and 2
id not have a follow-up study, 1 because of
izziness and the other patient was hospitalized for
cute cholecystitis in the interim. The remaining 20
atients completed the protocol, and 17 (85%)
atients received ranolazine 1,000 mg twice daily.
ild dizziness was reported by 6 (30%) patients, 3
f whom only received 500 mg twice daily for the
uration of 4 weeks. No other significant side
ffects were reported.
Baseline clinical and laboratory variables are
hown in Table 2. Most patients were receiving
spirin, beta-blockers, and statins at baseline. At
nrollment, 18 (95%) patients were in Canadian
ardiovascular Society anginal class II for angina
ectoris. Finally, in response to the question of
how do you feel since your first imaging study,” 15
75%) patients responded by saying they feel better
nd used several adjectives to describe their well-
eing as having more energy or feeling less fatigued,
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1304hich are difficult to quantify but clearly important
rom the patients’ perspective.
readmill exercise testing results. The end points of
xercise in the baseline study were as follows:
atigue in 14 patients, shortness of breath in 2
atients, and chest pain in 4 patients. In the
ollow-up study, the end points were as follows:
atigue in 14 patients, shortness of breath in 5
atients, and chest pain in 1 patient. The exercise
ime increased from 393  116 s to 425  105 s
fter ranolazine treatment (p  0.017, Fig. 1).
here were ST shifts consistent with ischemia in 6
30%) patients at baseline that persisted at follow-
p. There were no significant changes in heart rate,
Pre-Ranolazine
393
425
p=0.017
Post-Ranolazine
Change in Exercise Treadmill Times
exercise treadmill times (in seconds) before and after ranolazine
Table 2. Clinical and Laboratory Variable Distribution
Variable
Total Sample
(n  20)
Age (yrs) 64 9
Body mass index (kg/m2) 31 4
Women 6 (30)
Diabetes mellitus 10 (50)
Hypertension 18 (90)
Dyslipidemia 18 (90)
Smokers 6 (30)
History of coronary revascularization 15 (75)
Aspirin 19 (95)
Beta-blockers 17 (85)
Nitrates 8 (40)
Statins 17 (85)
Low-density lipoprotein (mg/dl) 84 21
Total cholesterol (mg/dl) 154 34
Glomerular ﬁltration rate (ml/min/1.73 m2) 71 14
Hematocrit (%) 39 4
No. of diseased vessels by coronary angiography 2 4
Values are mean  SD or n (%).a
e mean and SD values before and after treatment are shown.ut the systolic blood pressure was slightly lower on
anolazine therapy; the corrected QT intervals did
ot change (Table 3).
uantitative MPI. These results are shown in Table
and Figure 2. The resting perfusion pattern did
ot change, and hence the changes in perfusion
eflected the changes in reversible defects. There
as a trend toward a decrease in total perfusion
efect size and reversible defect size by polar maps
p  0.05) and a decrease in summed stress score
nd SDS (p  0.05) in the total group. The
ndividual responses are shown in Figure 2, and a
epresentative example is shown in Figure 3. Of
ote, 1 patient had no perfusion defect in the initial
nd follow-up studies by automated analysis even
hough on visual analysis, there was a suggestion of
mild inferior abnormality. He was nevertheless
ncluded in this analysis.
Based on side-by-side analysis, improvement in
he extent and severity of ischemia was noted in 14
70%) patients. The MPI results in these 14 pa-
ients are shown in Table 5. A significant decrease
as noted in the extent and severity of the total and
schemic perfusion defect size (all p values0.025).
There was no correlation between the change in
eversible perfusion defect size and change in exer-
ise time (r  0.17). However, of the 15 patients
ho had improvement in angina, 11 also had an
mprovement in perfusion pattern. There were no
nterval changes in ejection fraction and LV volume
fter ranolazine therapy (Table 4).
I S C U S S I O N
he main finding of this study is that an improve-
ent in perfusion pattern during exercise could be
emonstrated in most patients with CAD and
xercise-induced ischemia after short-term ranola-
ine treatment at comparable work loads. Most
atients who experienced clinical improvement also
ad improvement in MPI.
echanism of action of ranolazine. Several acquired,
ongenital, and pharmacological interventions are
nown to enhance late sodium current (7). This
urrent leads to an increase in intracellular sodium,
hich, via the sodium-calcium exchange, may cause
ellular calcium overload. The calcium overload
eads to electrical instability (afterdepolarization
nd arrhythmias) and mechanical dysfunction with
n increase in diastolic tension. Demand-ischemia
n patients with CAD such as that during exercise is
ne of the pathological conditions that presumablySe
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1305egets a deleterious positive feedback cycle as the
ctivation of the late sodium current leads to in-
reases in wall tension and further decreases the
BF (17). Ranolazine, by improving diastolic ten-
ion, leads to improvement in MBF (3). In animal
odels of occlusion-reperfusion, ranolazine im-
roved the MBF during reperfusion (11,12). It has
lso been shown that at therapeutic concentrations,
anolazine improves diastolic tension by shortening
epolarization in patients with type 3 long QT
yndrome (18).
Table 3. Comparison of Hemodynamic and Treadmill Exercise V
Pre-Ran
(n 
Resting heart rate (beats/min) 68
Peak heart rate (beats/min) 128
Resting systolic blood pressure (mm Hg) 133
Peak systolic blood pressure (mm Hg) 168
Resting diastolic blood pressure (mm Hg) 76
Peak diastolic blood pressure (mm Hg) 75
Exercise time (s) 393
Exercise METS 8
Resting QT (ms) 411
Peak QT (ms) 309
Values are mean  SD or n (%). *Paired t test.
METS  metabolic equivalents.
Table 4. Comparison of Myocardial Perfusion Variables Between
Pre-Ranolazin
(n  20)
PDS (% LV)
Total 24 15
Ischemia 15 10
Scar 9 9
PDS severity (% LV)
Mild (50%) 21 12
Moderate (26%–50%) 1.7 4.0
Severe (0%–25%) 0.6 2.0
Ischemia severity (% LV)
Mild (50%) 9 9
Moderate (26%–50%) 5 3
Severe (0%–25%) 0.7 2
Summed stress score 13 8
Summed rest score 5 6
Summed difference score 7.4 5.0
Gated SPECT variables
LV ejection fraction (%) 59 15
LV end-diastolic volume (ml) 112 54
LV end-systolic volume (ml) 52 45
Values are mean  SD or n (%). *Paired t test.
PDS  perfusion defect size; LV  left ventricle/ventricular; SPECT  single-photoIn pivotal phase 3 trials in patients with stable
ngina, ranolazine reduced anginal frequency and
rolonged the time to ST-segment depression dur-
ng exercise stress testing (5,9). In patients with
cute coronary syndromes (MERLIN–TIMI 36
Metabolic Efficiency with Ranolazine for Less
schemia in Non-ST-elevation Acute Coronary
yndrome–Thrombolysis In Myocardial Infarction
6] Randomized Controlled Trial), ranolazine
howed only a modest, nonsignificant effect on
schemia as detected by continuous electrocardio-
bles Between Baseline and Follow-Up Stress Tests
zine
)
Post-Ranolazine
(n  20) p Value*
68 8 0.74
129 22 0.67
128 14 0.14
160 28 0.04
75 7 0.77
78 9 0.42
6 425 105 0.017
8.3 2 0.18
419 33 0.2
306 48 0.70
seline and Follow-Up Stress Tests
Post-Ranolazine
(n  20) p Value*
20 13 0.09
11 8 0.12
9 11 1.0
18 10 0.054
2 4 1.0
0.6 3.0 1.0
7 6 0.2
4 4 0.36
0.5 1 0.60
10 7 0.04
5 6 0.2
4.7 4.0 0.0037
61 15 0.25
114 58 0.68
52 47 0.95aria
ola
20
10
20
23
27
16
12
11
2
29
59Ba
en emission computed tomography.
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1306raphic monitoring during the initial 7 days after
dmission, although it had a more robust effect on
linical events that occurred several days after ad-
ission (19,20). Ranolazine significantly improved
0
SSS
P=0.04
1013
8
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40
Pre-Ranolazine Post-Ranolazine
0
55
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20
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Pre-Ranolazin
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Pre-Ranolazin
Figure 2. Change in Quantitative Myocardial Perfusion Variable
Changes in summed stress score (SSS), summed rest score (SRS), an
ﬁxed (scar), and reversible (ischemia) defect size by polar maps (bo
Figure 3. Representative Example of Improvement in Myocardia
A representative example of exercise myocardial perfusion imaging
ment in myocardial perfusion in polar maps. Radionuclide injection
The raw images during stress before ranolazine (A, top panel), stre
are shown. Each panel shows serial slices from the apex to the bas
the vertical and horizontal long-axis projections. The perfusion defe
(14% absolute reduction) by polar maps, and the improvement is also vlycosylated hemoglobin (HbA1c) and recurrent
schemia in patients with diabetes mellitus and
educed the incidence of increased HbA1c in those
ithout known hyperglycemia (19–21).
S
5
Post-Ranolazine
0
SDS
P=0.0037
4.7
7.4
2
4
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Pre-Ranolazine Post-Ranolazine
r
9
ost-Ranolazine
S
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Ischemia
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5
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P=NS
Post-RanolazinePre-Ranolazine
mmed difference score (SDS) (top rows) and changes in total,
rows). The mean  SD values are shown in each panel.
rfusion by Single-Photon Emission Computed Tomography
ore and after ranolazine treatment showing quantitative improve-
performed at a peak heart rate of 142 beats/min in both tests.
ter ranolazine (B, middle panel), and at rest (C, bottom panel)
the short-axis projection and 1 slice at mid left ventricular level in
ize decreased from 25% to 11% of left ventricular myocardiumSRS
P=N
e
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1307Based on the new labeling of ranolazine as a
rst-line treatment, many patients with stable an-
ina, like those included in this study, may benefit
rom ranolazine therapy. Our preliminary findings
f improved myocardial perfusion after ranolazine
herapy suggest a noninvasive and objective method
f follow-up in such patients.
We are unaware of data in humans with ranola-
ine on either measurements of absolute MBF or
elative MBF (by means of MPI as was done in this
tudy) to confirm the animal data. We believe that
he improvement in myocardial perfusion reflects
mprovement in regional MBF and thus is consis-
ent with the previously stated hypothesis. The use
f MPI cannot answer the question of whether
here was a concomitant improvement in MBF in
emote normal zones.
revious studies. Multiple studies have shown that
ntiangina medications such as nitrates, beta-
lockers, first-generation calcium channel blockers,
nd statins can decrease the extent and severity of
eversible perfusion defects with serial MPI (2).
easurements of absolute MBF using positron
mission tomography provide supportive evidence
f the improved perfusion (rather than alternative
echanisms such as partial volume effect due to
melioration of ischemia and stunning). Most pre-
Table 5. Comparison of Myocardial Perfusion Variables Between
Improved Perfusion
Pre-Ranolazin
(n  14)
PDS (% LV)
Total 26 17
Ischemia 16 10
Scar 10 10
PDS severity (% LV)
Mild (50%) 23 13
Moderate (26%–50%) 2 5
Severe (0%–25%) 1 3
Ischemia severity (% LV)
Mild (50%) 10 9
Moderate (26%–50%) 5 4
Severe (0%–25%) 1 3
Summed stress score 14 9
Summed rest score 6 7
Summed difference score 8 5
Gated SPECT variables
LV ejection fraction (%) 56 15
LV end-diastolic volume (ml) 112 57
LV end-systolic volume (ml) 60 50
Values are mean  SD. *Paired t test.
Abbreviations as in Table 4.ious studies were based on the results of treadmill dxercise testing, but there are data to indicate that
mprovement in myocardial perfusion and MBF
ould be demonstrated using vasodilator stress test-
ng with adenosine or dipyridamole (2). Of note is
hat in almost all these studies, there is a consider-
ble interindividual variability in the degree of
mprovement, and our current results are in agree-
ent with these observations. Such variability was
lso noted in both arms of the nuclear substudy of
he COURAGE (Clinical Outcomes Utilizing Re-
ascularization and Aggressive Drug Evaluation)
rial, the optimum medical therapy alone and the
ptimal medical therapy plus coronary revascular-
zation (22).
uantitative automated MPI analysis. The Achilles
eel of many imaging modalities is the mode of
nterpreting the results. Quantitative automated
ethods are superior to qualitative methods. These
ssues were recently discussed in detail elsewhere
23,24). For example, in a recent trial in 2,000
atients who had 2 sets of vasodilator imaging
ithin a short period of time, the agreement rates of
he presence and extent of perfusion abnormality
ere 60% by visual analysis and 90% by auto-
ated quantitative analysis (16). It is because of this
eason that analysis in this study was based entirely
n automated quantitative methods. The perfusion
seline and Follow-Up Stress Tests Among Those Who Had
Post-Ranolazine
(n  14) p Value*
19 15 0.002
8 6 0.003
11 13 0.76
16 10 0.004
2 4 0.17
1 3 1.0
4 3 0.02
3 4 0.08
1 1 0.5
10 8 0.0001
6 7 0.74
4 3 0.0001
58 16 0.17
120 63 0.84
59 53 0.66Ba
eefect size is the extent of perfusion defect ex-
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1308ressed as the percentage of the left ventricle. The
DS, however, is based on both the extent and
everity of the perfusion defect. Thus, an improve-
ent in severity will be reflected in the SDS but not
n the perfusion defect size. The improvement in
he severity of the ischemia was apparent on visual
ssessment in the side-by-side analysis and con-
rmed by the automated analysis.
tudy limitations. Our study has several limitations:
hese include the size, single-center study, and
he lack of randomization or a control arm. The
tudy design may have biased the observed im-
rovement in exercise time with ranolazine, espe-
ially in the absence of a placebo arm. Regression to
he mean in SPECT results or a training effect is
lausible; however, our study should be considered
ypothesis-generating, and more definitive studies
ith larger numbers of patients are needed. Our
atients are likely to be representative of other
atients with known CAD undergoing exercise
esting in terms of total and reversible perfusionSweeney M, Kloner RA. Late sodium
current inhibition as a new cardiopro-
of the late sodium
macol Exp Ther 2O N C L U S I O N S
n this preliminary hypothesis-driven study, short-
erm ranolazine therapy was shown to improve
yocardial perfusion and decrease the ischemic
urden in patients with CAD. These findings
ight have far-reaching ramifications as to how to
efine optimal medical therapy and how best to
ssess the effectiveness of such a therapy. Is it by
linical response, electrocardiographic response, or
xercise time, or does it require imaging? The
nswers to these questions can only be obtained by
uture carefully designed larger studies.
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